生物治疗药物的高自信免疫性风险评估的MHC II MAPP
Elise Pepermans1, Zuben E Sauna2, Sofie Pattyn3
1ImmuneSpec, Niel, Belgium. Elise.Pepermans@ImmuneSpec.com.
Methods in molecular biology (Clifton, N.J.)
|October 14, 2025
概括
免疫性风险评估对于生物疗法至关重要. 一个新的MHC II MAPPs测定协议识别了由HLAII类呈现的特定,改善了药物安全性和有效性评估.
科学领域:
- 生物制药的发展.
- 免疫学 免疫学 免疫学
- 蛋白质组学是指蛋白质组学.
背景情况:
- 生物治疗药物可以引起免疫性,影响药物的安全性和有效性.
- 评估免疫性包括了解抗原呈现细胞 (APC) 的蛋白质处理和通过MHCII类 (HLAII类) 的呈现.
- 目前的方法可能无法完全捕捉体内加工和呈现的场景.
研究的目的:
- 描述一个MHC II相关蛋白质组学 (MAPPs) 试验的强大协议.
- 为了能够识别由单个MHC II变异呈现的治疗性蛋白质衍生.
- 加强对生物治疗药物的免疫性风险评估.
主要方法:
- 为MHC II MAPPs开发和验证一个高度可靠的协议.
- 使用MAPP来分析来自治疗蛋白质的.
- 描述与免疫反应相关的-MHC II 复合体.
主要成果:
- 描述的协议为MHC II MAPPs提供了一种可靠的方法.
- 该试验从与MHC II分子结合的治疗性蛋白质中识别出特定的.
- 这为免疫性相关的加工和呈现步骤提供了洞察力.
结论:
- 强大的MHC II MAPPs协议是生物制药开发的宝贵工具.
- 这种测试有助于预测和理解T细胞对生物治疗药物的反应.
- 改进的免疫性评估有助于更安全,更有效的药物开发.
相关概念视频
01:26Antigens Involved in Adaptive Immunity
1.3K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
1.3K
01:31Antigen Processing Pathways
2.1K
MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
MHC Class I: Presenting Endogenous...
2.1K